Northland Capital Markets Downgrades Oncternal Therapeutics to Market Perform, Announces $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
Northland Capital Markets has downgraded Oncternal Therapeutics from Outperform to Market Perform, setting a price target of $2.
September 12, 2024 | 7:49 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Oncternal Therapeutics has been downgraded by Northland Capital Markets from Outperform to Market Perform, with a new price target of $2.
The downgrade from Outperform to Market Perform suggests a less optimistic outlook for Oncternal Therapeutics, which could lead to a negative short-term impact on its stock price. The $2 price target indicates limited upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100